The use of pembrolizumab and lenvatinib combination therapy in endometrial cancer: an examination of toxicity and treatment efficacy in clinical practice
Jeffrey How(The University of Texas MD Anderson Cancer Center), Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), Pamela T. Soliman(The University of Texas MD Anderson Cancer Center), Lois M. Ramondetta(The University of Texas MD Anderson Cancer Center), Karen H. Lu(The University of Texas MD Anderson Cancer Center), Bryan Fellman(The University of Texas MD Anderson Cancer Center), Nicole D. Fleming(The University of Texas MD Anderson Cancer Center), Shrina Patel(The University of Texas MD Anderson Cancer Center), Shannon N. Westin(The University of Texas MD Anderson Cancer Center)
Cited by 2
Related Papers
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance
|Nature Medicine|2023|508
Gene Expression Profiles of BRCA1-Linked, BRCA2-Linked, and Sporadic Ovarian Cancers
|JNCI Journal of the National Cancer Institute|2002|285